Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study.

Abstract:

:The antiemetic efficacy and tolerability of four different oral doses of granisetron (0.25, 0.5, 1, and 2 mg twice daily [BID]) were compared in a randomized, double-blind, parallel-group, multicenter study involving 930 patients with malignant disease receiving moderately emetogenic chemotherapy over a 7- or 14-day period. On the first day of granisetron treatment, a statistically significant association between complete response and dose was seen (P = 0.001), with the maximum response (81.1%) achieved at a dose of 1 mg BID. The 24-hour complete response rate with granisetron 1 mg BID was significantly higher than with 0.25 mg BID (61.1%) or 0.5 mg BID (70.2%) (P < 0.009). The complete response rate for days 0 to 6 was significantly higher with granisetron at 1 mg BID (58.8%) than with 0.25 mg BID (43.7%) or 0.5 mg BID (53.6%) (P < 0.009). No advantage in terms of complete response rate was shown for 2 mg BID over 1 mg BID. Granisetron was well tolerated, and few patients required additional treatment with other antiemetics.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Bleiberg HH,Spielmann M,Falkson G,Romain D

doi

10.1016/0149-2918(95)80005-0

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

38-51

issue

1

eissn

0149-2918

issn

1879-114X

pii

0149-2918(95)80005-0

journal_volume

17

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Chronic functional dyspepsia: short- and medium-term outcome of a therapeutic trial with cisapride.

    abstract::In an open, multicenter trial, 329 patients (who attended gastroenterology practices or outpatient gastroenterology departments of hospitals) with a mean age of 47.3 years, received 5 mg of cisapride three times a day (TID) for at least 2 weeks for the treatment of persistent, recurring symptoms of functional dyspepsi...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Rösch W

    更新日期:1994-05-01 00:00:00

  • Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.

    abstract:BACKGROUND:Bisphosphonates are the class of medication used most widely to treat osteoporosis. Since an article reported that patients who used zoledronic acid, a bisphosphonate, had a higher proportion of atrial fibrillation (AF) in 2007, the issue of bisphosphonates and AF has become a growing concern. Due to the wid...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2011.07.012

    authors: Lu PY,Hsieh CF,Tsai YW,Huang WF

    更新日期:2011-09-01 00:00:00

  • Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.

    abstract:BACKGROUND:Short-term studies have demonstrated a modest weight-reducing to weight-neutral effect among patients receiving bupropion sustained-release (SR) for the treatment of depression. OBJECTIVE:This study was conducted to evaluate the long-term effects of bupropion SR on body weight in patients with depression. ...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(02)85141-4

    authors: Croft H,Houser TL,Jamerson BD,Leadbetter R,Bolden-Watson C,Donahue R,Metz A

    更新日期:2002-04-01 00:00:00

  • Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.

    abstract:OBJECTIVE:This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan Dosing Aid, Alcon Research Ltd., Fort Worth, Texas). METHODS:The study had an open-label, multi...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.clinthera.2006.11.001

    authors: Flowers B,Wand M,Piltz-Seymour J,Berke SJ,Day D,Teague J,Smoot TM,Landry TA,Bergamini MV,Mallick S,Travatan Dosing Aid Study Group.

    更新日期:2006-11-01 00:00:00

  • Genetic mechanisms of psychosis: in vivo and postmortem genomics.

    abstract:BACKGROUND:The Clinical Brain Disorders Branch Sibling Study data set was initiated in 1996 to examine genetic associations and to identify biological traits associated with susceptibility gene effects. Characterizing genes--and translating their effects on brain development and function--has potential implications for...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2005.07.016

    authors: Weinberger DR

    更新日期:2005-01-01 00:00:00

  • Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.

    abstract:BACKGROUND:Most marketed artificial tears are substitutes for the aqueous layers of the tear film; therefore, frequent instillation of artificial tears is necessary. Newer gel-, cellulose-, and mineral oil-based formulations have been designed to overcome the disadvantages of current aqueous tear substitutes by offerin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2010.01.024

    authors: Wang TJ,Wang IJ,Ho JD,Chou HC,Lin SY,Huang MC

    更新日期:2010-01-01 00:00:00

  • Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin.

    abstract:PURPOSE:Polycystic ovary syndrome (PCOS) is a metabolic and endocrinal disorder affecting a number of women of reproductive age. We aimed to reveal the correlation between the endocannabinoid system and PCOS, which may provide a new therapeutic target for PCOS treatment. METHODS:Serum levels of anandamide and 2-arachi...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2017.02.007

    authors: Cui N,Feng X,Zhao Z,Zhang J,Xu Y,Wang L,Hao G

    更新日期:2017-04-01 00:00:00

  • Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis.

    abstract::Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid family with demonstrated efficacy in the treatment of rheumatoid arthritis and osteoarthritis; a distinguished safety profile; and good tolerability. This report describes a new extended-release formulation that maintains therapeutic pla...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Schumacher HR Jr

    更新日期:1994-03-01 00:00:00

  • Intravenous nicardipine: cardiovascular effects and clinical relevance.

    abstract::Nicardipine hydrochloride is the first intravenous dihydropyridine calcium antagonist to become available in the United States. Its chemical structure makes it unique among its drug class and confers clinically useful properties for the treatment of acute cardiovascular conditions, such as ischemia, hypertension, cong...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Pepine CJ

    更新日期:1988-01-01 00:00:00

  • Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

    abstract:PURPOSE:New therapies, including daratumumab plus lenalidomide plus dexamethasone (DRd) and daratumumab plus bortezomib plus dexamethasone (DVd), have recently been approved in the United States for patients with multiple myeloma (MM) who have received at least 1 prior line of therapy. However, few treatments have been...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clinthera.2018.01.014

    authors: Maiese EM,Ainsworth C,Le Moine JG,Ahdesmäki O,Bell J,Hawe E

    更新日期:2018-03-01 00:00:00

  • Mononitrates: defining the ideal long-acting nitrate.

    abstract::As a result of recent advances in our understanding of the role of nitric oxide and endothelial-derived relaxing factor (EDRF) in vascular control, physicians now have the potential to overcome the loss of EDRF effect by administering nitrates. Nitrates are converted to nitric oxide, resulting in vasodilator effects t...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Frishman WH,Amsterdam E,Glasser SP,Thadani U

    更新日期:1994-03-01 00:00:00

  • Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial.

    abstract:BACKGROUND:Dementia is a cerebral disorder resulting in a progressive deterioration of intellectual function that compromises the patient's ability to function. The diagnostic criteria for dementia are primarily clinical and are based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Hac...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/S0149-2918(00)80056-9

    authors: Emeriau JP,Lehert P,Mosnier M

    更新日期:2000-07-01 00:00:00

  • Why Are We Still Creating Individual Case Safety Reports?

    abstract::The history of drug safety monitoring, or pharmacovigilance, has been an interesting one. Despite many and ongoing changes, it has typically been characterized by a rather slow-moving and reactive progression. Pharmacovigilance has always lagged behind other fields and industries and has been slow to adapt to new appr...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2018.10.012

    authors: Streefland MB

    更新日期:2018-12-01 00:00:00

  • Treating hypertension to reduce cardiovascular risk: a Korean perspective.

    abstract:BACKGROUND:Hypertension usually clusters with other cardiovascular risk factors; however, it has not been reported whether hypertension treatment has an impact on the awareness and treatment of other cardiovascular risk factors such as diabetes mellitus and hypercholesterolemia. OBJECTIVE:To analyze the effect of hype...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.05.006

    authors: Kim KI,Kim CH

    更新日期:2012-07-01 00:00:00

  • Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.

    abstract:PURPOSE:We assessed the effects of coadministration of metformin and teneligliptin on their pharmacokinetics in steady-state conditions relative to the administration of either drug alone. METHODS:This was a Phase I, single-center, open-label, 2-way parallel-group study in healthy male and female subjects. Subjects in...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2015.06.012

    authors: Nakamaru Y,Hayashi Y,Davies M,Jürgen Heuer H,Hisanaga N,Akimoto K

    更新日期:2015-09-01 00:00:00

  • Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

    abstract::This multicenter, randomized, double-blind study compared the efficacy and tolerability of ondansetron 8 mg twice daily for 3 days with placebo in preventing nausea and vomiting in 81 patients receiving cyclophosphamide-doxorubicin-based chemotherapy. The first dose of study drug was administered 30 minutes before the...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/0149-2918(95)80087-5

    authors: DiBenedetto J Jr,Cubeddu LX,Ryan T,Kish JA,Sciortino D,Beall C,Eisenberg PD,Henderson C,Griffin D,Wentz A

    更新日期:1995-11-01 00:00:00

  • Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

    abstract:PURPOSE:The purpose of this study was to compare the bioavailability between 2 milk thistle-containing dietary supplements, Product B and IsaGenesis, in healthy volunteers. METHODS:Bioavailability between Product B, originally formulated as a powdered capsule, and IsaGenesis, reformulated as a soft gel, were compared ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2017.11.013

    authors: Li WY,Yu G,Hogan RM,Mohandas R,Frye RF,Gumpricht E,Markowitz JS

    更新日期:2018-01-01 00:00:00

  • Ceftazidime/metronidazole versus netilmicin/metronidazole in the treatment of perforated appendicitis in children.

    abstract::One hundred children with peritonitis resulting from a perforated appendix were treated with ceftazidime or netilmicin. Metronidazole was added to both groups to treat the anaerobic organisms commonly associated with the infecting aerobic organisms in peritonitis. Escherichia coli was the most common aerobe found in p...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kooi GH,Pit S

    更新日期:1990-01-01 00:00:00

  • Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten

    abstract:BACKGROUND:Patients with hypertension may require combination therapy to attain the blood pressure targets recommended by US and European treatment guidelines. Combination therapy with a calcium channel blocker and an angiotensin II-receptor blocker would be expected to provide enhanced efficacy. OBJECTIVES:Two studie...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2007.03.018

    authors: Philipp T,Smith TR,Glazer R,Wernsing M,Yen J,Jin J,Schneider H,Pospiech R

    更新日期:2007-04-01 00:00:00

  • The Cardiac Injury Immune Response as a Target for Regenerative and Cellular Therapies.

    abstract:PURPOSE:Despite modern reperfusion and pharmacologic therapies, myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Therefore, the development of further therapeutics affecting post-MI recovery poses significant benefits. This review focuses on the post-MI immune response and immuno...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2020.09.006

    authors: Hume RD,Chong JJH

    更新日期:2020-10-01 00:00:00

  • Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center.

    abstract::This pilot study was conducted to compare both the clinical effectiveness and the treatment costs of newer (atypical) antipsychotic medications (clozapine and risperidone) with those of older (classic) neuroleptic medications (chlorpromazine and haloperidol) for psychosis in a community mental health care setting. The...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0149-2918(99)80028-9

    authors: Galvin PM,Knezek LD,Rush AJ,Toprac MG,Johnson B

    更新日期:1999-06-01 00:00:00

  • Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.

    abstract:BACKGROUND:Diabetes mellitus (DM) is a powerful independent risk factor for multivessel, diffuse coronary artery disease (CAD). The optimal coronary revascularization strategy in DM is not clearly defined, but past trials have suggested an advantage for coronary artery bypass grafting (CABG). Recently, the Future Revas...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2013.07.427

    authors: Burgess SN,Mussap CJ,French JK

    更新日期:2013-08-01 00:00:00

  • Trends in off-label beta-blocker use: a secondary data analysis.

    abstract:BACKGROUND:The off-label use of beta-blockers might be prevalent, but no studies have provided empiric data on the off-label use based on utilization data. OBJECTIVE:This secondary data analysis was conducted to describe the trends of off-label use of beta-blockers among ambulatory visits made to office-based physicia...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2006.10.015

    authors: Lin HW,Phan K,Lin SJ

    更新日期:2006-10-01 00:00:00

  • Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.

    abstract:BACKGROUND:Varenicline was designed to relieve symptoms of nicotine withdrawal, including cigarette craving, and to block the reinforcing effects of continued nicotine use. The cost-effectiveness of varenicline in some countries has not been studied. OBJECTIVE:The aim of this study was to compare the cost-effectivenes...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.07.002

    authors: Athanasakis K,Igoumenidis M,Karampli E,Vitsou E,Sykara G,Kyriopoulos J

    更新日期:2012-08-01 00:00:00

  • Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus.

    abstract::This study sought to compare the efficacy and safety of glyburide and glipizide in elderly patients with well-controlled non-insulin-dependent diabetes mellitus (NIDDM). One hundred forty-five patients aged > or = 65 years with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy were enrolle...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Rosenstock J,Corrao PJ,Goldberg RB,Kilo C

    更新日期:1993-11-01 00:00:00

  • Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

    abstract:BACKGROUND:Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against both wild-type HIV and viruses harboring NNRTI resistance. Etravirine is mainly eliminated via the hepatobiliary route. OBJECTIVES:This study in HIV- patients with mild or moderate hepatic impairment and healthy mat...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2010.02.013

    authors: Schöller-Gyüre M,Kakuda TN,De Smedt G,Woodfall B,Berckmans C,Peeters M,Hoetelmans RM

    更新日期:2010-02-01 00:00:00

  • Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.

    abstract:PURPOSE:Long-acting insulin analogues were developed to facilitate consistent glycemic control without excessive hypoglycemia. However, structural modifications of the insulin molecule can alter biological responses and binding characteristics with specific receptors. The aim of this study was to estimate the risk of s...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.06.031

    authors: Lin JC,Shau WY,Lai MS

    更新日期:2014-09-01 00:00:00

  • Results of prifinium bromide therapy in irritable bowel syndrome.

    abstract::An open clinical trial with prifinium bromide, an anticholinergic agent, was carried out in 21 patients with irritable bowel syndrome showing clear psychosomatic characteristics. The clinical efficacy was evaluated by comparing the symptomatic severity before, during, and after treatment with prifinium bromide, 90 mg/...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Sasaki T,Takekoshi T,Okada T

    更新日期:1985-01-01 00:00:00

  • A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.

    abstract:BACKGROUND:Oxymorphone extended release (ER) is a tablet formulation of the mu-opioid agonist oxymorphone designed to achieve a low peak-to-trough fluctuation in plasma concentrations over a 12-hour dosing period. OBJECTIVE:This study compared the analgesic efficacy, dose response, and tolerability of 3 doses of oxymo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2006.03.008

    authors: Kivitz A,Ma C,Ahdieh H,Galer BS

    更新日期:2006-03-01 00:00:00

  • Rotavirus live, oral, pentavalent vaccine.

    abstract:BACKGROUND:On February 3, 2006, the US Food and Drug Administration (FDA) approved a live, oral, pentavalent (G1-G4, P1[8]) human-bovine reassortant rotavirus vaccine for the prevention of rotavirus gastroenteritis (RVGE) in infants in the United States. The Advisory Committee of Immunization Practices of the Centers f...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.12.018

    authors: Tom-Revzon C

    更新日期:2007-12-01 00:00:00